Maravai LifeSciences (NASDAQ:MRVI) Announces Earnings Results

Maravai LifeSciences (NASDAQ:MRVI) posted its earnings results on Wednesday. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.03, FiscalAI reports. Maravai LifeSciences had a negative return on equity of 15.70% and a negative net margin of 37.07%. The company had revenue of $45.85 million during the quarter, compared to analyst estimates of $43.56 million.

Here are the key takeaways from Maravai LifeSciences’ conference call:

• Q3 revenue rose 10% to $45.9 million, led by mRNA growth of 28% (GMP consumables +30%, discovery mRNA +27%). Cygnus grew 8%, marking its sixth consecutive quarter of year-over-year growth.
• Adjusted EBITDA improved by $16.6 million year over year to $5.8 million, and Maravai raised its 2026 revenue outlook to $212–$216 million and adjusted EBITDA outlook to $40–$42 million.
• Management cited a healthy mRNA pipeline and growing customer adoption: 10 discovery customers transitioned to clinical-stage GMP year to date, surpassing the company’s target of nine, and more than 180 customers are using ModTail.
• Management cautioned that GMP and CDMO orders are program-driven and can vary significantly by quarter; it expects GMP activity to skew toward the second half of 2027 and does not anticipate substantial 2027 GMP revenue from ModTail. Specialty chemistry revenue also declined 4% as large prior-year orders did not repeat.

Maravai LifeSciences Stock Performance

Shares of NASDAQ:MRVI traded up $0.27 during trading on Wednesday, reaching $7.71. The company had a trading volume of 3,624,037 shares, compared to its average volume of 2,400,230. The firm’s fifty day moving average is $7.45 and its 200 day moving average is $5.27. The company has a current ratio of 4.05, a quick ratio of 2.98 and a debt-to-equity ratio of 0.49. Maravai LifeSciences has a twelve month low of $2.55 and a twelve month high of $9.42.

Analyst Ratings Changes

A number of research firms recently weighed in on MRVI. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maravai LifeSciences in a report on Wednesday, August 26th. Wall Street Zen lowered shares of Maravai LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, August 29th. TD Cowen began coverage on shares of Maravai LifeSciences in a research report on Monday, October 5th. They issued a “buy” rating and a $9.00 target price for the company. Wells Fargo & Company raised their price target on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, UBS Group lifted their price target on Maravai LifeSciences from $2.50 to $8.00 and gave the company a “neutral” rating in a report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Maravai LifeSciences currently has a consensus rating of “Moderate Buy” and an average price target of $7.38.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc is a life sciences company that provides products and services used in the development, manufacture and quality testing of biopharmaceuticals, vaccines and diagnostic products. The company serves pharmaceutical, biotechnology, academic and other research organizations involved in nucleic acid and biologics development.

Through its TriLink BioTechnologies business, Maravai supplies specialized nucleic acid products and services, including modified nucleotides, messenger RNA-related materials, enzymes and other components used in research and biomanufacturing.